![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, September 04, 2018 4:48:29 PM
Propanc Biopharma Inc (PPCB) stock has bounced back to life on news the company has entered a national phase on two key patents for cancer treatment. Also PPCB benefit from the "Right to Try Act"President Trump signed aimed at allowing terminally ill patients a right to try a drug that is not currently FDA approved. This is a really major development for innovative biotech like PPCB.
Price action points to further movements on the upside as the upward momentum continues to gather pace, the stock should be on its way back to this year’s highs of $0.77 a share.
Recent PPCB News
- Biopharma on a Tear After Certificate of Grant from Japanese Patent Office • AllPennyStocks.com • 06/25/2024 04:26:00 PM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM